147 related articles for article (PubMed ID: 36354067)
1. Understanding the parameters guiding the best practice for treating B-cell-depleted patients with COVID-19 convalescent plasma therapy.
Gachoud D; Bertelli C; Rufer N
Br J Haematol; 2023 Jan; 200(2):e25-e27. PubMed ID: 36354067
[No Abstract] [Full Text] [Related]
2. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Kremer AE; Kremer AN; Willam C; Völkl S; Verhagen J; Achenbach S; van der Meijden ED; Lang V; Aigner M; Maier C; Tenbusch M; Korn K; Lutzny-Geier G; Spoerl S; Strauß R; Vetter M; Überla K; Neurath MF; Mackensen A; Schiffer M; Hackstein H
Eur J Immunol; 2021 Oct; 51(10):2478-2484. PubMed ID: 34350584
[TBL] [Abstract][Full Text] [Related]
3. Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell-Depleted Patients.
Gharbharan A; GeurtsvanKessel CH; Jordans CCE; Blaauw M; van der Klift M; Hassing RJ; Smits-Zwinkels M; Meertens M; van den Hout EC; de Man AM; Hageman I; Bogers S; van der Schoot CE; Swaneveld F; Anas AA; Rokx C; Rijnders BJA
Clin Infect Dis; 2022 Apr; 74(7):1271-1274. PubMed ID: 34293119
[TBL] [Abstract][Full Text] [Related]
4. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
5. Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations.
Focosi D; Franchini M
Expert Rev Vaccines; 2022 Jul; 21(7):877-884. PubMed ID: 34015243
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.
Casadevall A; Henderson JP; Joyner MJ; Pirofski LA
J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33621214
[No Abstract] [Full Text] [Related]
7. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.
Basheer M; Saad E; Laskar O; Schuster O; Rechnitzer H; Zisman-Rozen S; Azoulay D; Assy N
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445605
[TBL] [Abstract][Full Text] [Related]
8. Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients.
Thümmler L; Lindemann M; Horn PA; Lenz V; Konik M; Gäckler A; Boss K; Theodoropoulos F; Besa V; Taube C; Brenner T; Witzke O; Krawczyk A; Rohn H
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680159
[TBL] [Abstract][Full Text] [Related]
9. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products.
Kenig A; Ishay Y; Kharouf F; Rubin L
Clin Immunol; 2021 Jun; 227():108723. PubMed ID: 33838340
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of anti-SARS-CoV-2 antibodies in repeat convalescent plasma donors.
Franchini M; Glingani C; Liumbruno GM; Mengoli C
Transfus Apher Sci; 2021 Dec; 60(6):103216. PubMed ID: 34315677
[No Abstract] [Full Text] [Related]
11. Thinking more about therapy with convalescent plasma for COVID-19 patients.
Han G; Zhou YH
Hum Vaccin Immunother; 2020 Nov; 16(11):2601-2603. PubMed ID: 32643512
[No Abstract] [Full Text] [Related]
12. COVID-19 convalescent plasma composition and immunological effects in severe patients.
Acosta-Ampudia Y; Monsalve DM; Rojas M; Rodríguez Y; Gallo JE; Salazar-Uribe JC; Santander MJ; Cala MP; Zapata W; Zapata MI; Manrique R; Pardo-Oviedo JM; Camacho B; Ramírez-Santana C; Anaya JM;
J Autoimmun; 2021 Mar; 118():102598. PubMed ID: 33524876
[TBL] [Abstract][Full Text] [Related]
13. Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report.
Nyström K; Hjorth M; Fust R; Nilsdotter-Augustinsson Å; Larsson M; Niward K; Nyström S
BMC Infect Dis; 2022 Apr; 22(1):362. PubMed ID: 35410137
[TBL] [Abstract][Full Text] [Related]
14. [COVID-19: Still a place for the convalescent plasma? Focus on the immunocompromised patients].
Richier Q; Hueso T; Tiberghien P; Lacombe K
Rev Med Interne; 2023 Sep; 44(9):467-471. PubMed ID: 37689526
[No Abstract] [Full Text] [Related]
15. Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2.
Müller K; Girl P; Giebl A; von Buttlar H; Dobler G; Bugert JJ; Gruetzner S; Wölfel R
J Clin Virol; 2021 Sep; 142():104912. PubMed ID: 34298379
[TBL] [Abstract][Full Text] [Related]
16. Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS-CoV-2.
Richier Q; De Valence B; Chopin D; Gras E; Levi LI; Abi Aad Y; Pacanowski J; Meynard JL; Plaçais L; Fey D; Couture P; Martin-Blondel G; Pestre V; Woessner J; Ancellin S; Weyrich P; Carpentier B; Idri S; Tiberghien P; Surgers L; Hueso T; Lacombe K
Influenza Other Respir Viruses; 2024 Mar; 18(3):e13272. PubMed ID: 38501337
[TBL] [Abstract][Full Text] [Related]
17. High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response).
De Santis GC; Calado RT
Emerg Infect Dis; 2022 May; 28(5):1083-1084. PubMed ID: 35447061
[No Abstract] [Full Text] [Related]
18. Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma.
Franchini M; Baldanti F; Percivalle E; Ferrari A; Biasi P; Liumbruno GM; Glingani C
Transfus Clin Biol; 2022 Feb; 29(1):101-102. PubMed ID: 34391625
[No Abstract] [Full Text] [Related]
19. Correlation between ABO blood group and neutralizing anti-SARS-CoV-2 antibody titers in convalescent plasma donations.
Franchini M; Mengoli C; Ballotari A; Glingani C
Transfus Clin Biol; 2022 May; 29(2):186-187. PubMed ID: 34690072
[No Abstract] [Full Text] [Related]
20. Measuring accuracy of the neutralizing activity of COVID-19 convalescent plasma.
Franchini M; Mengoli C; Caruso B; Petilino R; Ballotari A; Glingani C
Clin Chem Lab Med; 2022 Jan; 60(1):e4-e6. PubMed ID: 34472761
[No Abstract] [Full Text] [Related]
[Next] [New Search]
